A Descriptive, Phase IV, Open-label, Single-arm Multi-center Study to Assess the Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Healthy Toddlers 12 to 23 Months of Age Who Had Been Primed With at Least 1 Dose of Another Quadrivalent Meningococcal Conjugate Vaccine, ie, Nimenrix® (MCV4-TT) or Menveo® (MCV4-CRM), in Infancy.
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 25 Sep 2024 Status changed from recruiting to completed.
- 29 May 2024 Planned End Date changed from 12 Aug 2024 to 17 Sep 2024.
- 29 May 2024 Planned primary completion date changed from 19 Apr 2024 to 17 Sep 2024.